Exelixis as of March 31, 2026 presents a positive liquidation recovery posture relative to most pharmaceutical going concerns, driven by a large, liquid financial asset base with minimal financial debt. Total assets of $2.59B are dominated by cash, cash equivalents, and marketable securities totaling $1.43B (cash $226M plus current marketable securities $551M plus non-current marketable securities $649M), all of which receive near-100% recovery under liquidation. Applying standard haircuts: cash/equivalents at 100% yields ~$226M; marketable securities (investment-grade corporate bonds, commercial paper, Treasuries, CDs) at 95% yields ~$1.21B; receivables of $329M at 90% yields ~$296M; inventory of $64M gross (split $27M current/$37M non-current) at 60% yields ~$38M; PP&E of $96M at 60% yields ~$57M; deferred tax assets of $294M at 0% (no value in liquidation); goodwill of $64M at 0%; intangibles/IP at 0%. Approximate gross liquidation asset recovery totals roughly $1.84B. Total liabilities at face value are $658M, comprising current liabilities of $371M (accounts payable $24M, accrued compensation $88M, customer refund liabilities $66M, other current liabilities $100M, deferred revenue current $1M, operating lease current portion embedded in other current liabilities) and non-current liabilities of $287M (non-current operating lease liability $170M, other non-current liabilities $117M, deferred revenue non-current $5M). No long-term financial debt is carried on the balance sheet. Approximate net liquidation recovery to equity is roughly $1.18B positive, suggesting EXEL is among the relatively rare pharma going concerns that would show meaningful positive recovery in a hypothetical liquidation—driven entirely by its cash-equivalent financial asset pile, not by operating asset value. The $236M decline in cash and marketable securities QoQ from $1.66B (Dec 31, 2025) to $1.43B (Mar 31, 2026) is primarily attributable to $430M in share repurchases under the October 2025 SRP, partially offset by $252M in operating cash generation. This cash consumption trend is material to the liquidation asset base. The non-current operating lease liability of $170M is a hard face-value claim in liquidation (ASC 842 ROU obligations do not extinguish). Contingent ANDA patent litigation (MSN, Azurity) and IRA/MFN drug pricing risks are balance-sheet-neutral currently but represent unquantified contingent liabilities not separately tagged. The filing discusses unrecognized stock-based compensation of $367M for RSUs in MD&A but this does not appear as a tagged balance sheet liability—it is a future cash/dilution obligation, not a face-value claim in liquidation.
▼ Community Notes